Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order
The White House
This executive order directs federal agencies to prevent foreign nations from "freeloading" on American pharmaceutical innovation by forcing drug manufacturers to offer United States consumers the lowest available global price.
The primary directive instructs the Department of Health and Human Services (HHS) to set "most-favored-nation" price targets, ensuring Americans pay the same low prices negotiated by other developed countries.
This is a direct attack on high pharmacy bills. By targeting the current system where drug companies heavily discount medications overseas while inflating prices at home, the administration aims to slash out-of-pocket costs for essential prescriptions.
If drug makers refuse to lower domestic prices voluntarily, the order authorizes aggressive fallback measures to force compliance.
HHS and the FDA are instructed to explore the safe, case-by-case importation of cheaper drugs from other nations and to facilitate direct-to-consumer purchasing programs.
Additionally, the Department of Justice and the Federal Trade Commission are directed to investigate pharmaceutical companies for anti-competitive behavior if they fail to adjust their pricing models.
